Our results suggest that the antitumour effects of gefitinib might offer a new therapeutic approach in anaplastic thyroid carcinoma when functional expression of EGFR is observed. The gene discussed is EGFR; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.